Kalaris Therapeutics, Inc.
KLRSHeld by 4 specialist biotech funds
High Convergence4 funds opened new positions. Short interest: 4.0% of float.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.